NewsRoom Articles - Page 91 of 154 - PsychedelicNewsWire (PNW)

FridayJul 16, 2021 1:45 pm

Dissociation, Dissociative Disorders and Dissociative Psychedelics

The world is deeply interconnected, and we as people may sometimes feel overwhelmed by the happenings in the outside world. If an individual is overwhelmed, their body allows them to disconnect by removing their attention from the present as a form of healthy escape. Called disconnection or dissociation, this is a physiological response to protect oneself, which is activated when the body feels overwhelmed or saturated by too much information or input. There are various kinds of dissociation, including dissociation from one’s sense of self, identity or biographical history; dissociation from one’s awareness or thoughts; and dissociation from one's bodily…

FridayJul 16, 2021 10:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Agreement with University of Michigan for Testing of Latest Psychedelic Drug Candidate

San Diego-based Tryp Therapeutics is developing new drug candidates with the aim of treating medical conditions that currently have limited effective therapy Tryp has solidified an agreement with the University of Michigan’s Chronic Pain & Fatigue Research Center and the Center for Consciousness Science to test synthetic psychedelic drug candidate TRP-8803 to advance its use in upcoming clinical trials The Company has also established an agreement with the University of Florida to test its lead drug candidate — TRP-8802 — for certain eating disorders Psychedelics are beginning to gain new respect and attention for addressing select neurological conditions as scientists,…

ThursdayJul 15, 2021 1:30 pm

Study Finds Mescaline May Trigger Improvements in Psychiatric Symptoms

An exploratory study that was recently published in the “ACS Pharmacology and Translational Science” journal has found that using mescaline has been linked to improvements in anxiety and depression. Mescaline is a psychedelic hallucinogen derived from the peyote cactus. This study provides evidence that some of the useful effects of mescaline are associated with certain facets of the psychedelic experience. Prior research suggests that the use of classic psychedelics may have long-term positive effects. However, the use of mescaline among Native American tribes hasn’t received as much attention as other substances, such as psilocybin. In the study, the researchers note…

WednesdayJul 14, 2021 2:30 pm

Research Suggests Users of Psychedelics Reframe Unpleasant Trips

A study recently asked users of psychedelic substances to share their experiences with the drugs and, in particular, their bad trips. The study, which was reported in the “International Journal of Drug Policy,” found that many users of psychedelic substances used storytelling to redefine bad trips and make them positive experiences. Hallucinogens, or psychedelics, are psychoactive substances that activate altered states of consciousness, influencing an individual’s cognition, perception and mood. Hallucinogens are considered to be low in toxicity and aren’t addictive, but they can sometimes cause challenging trips, which are basically negative reactions that can include frightening hallucinations, panic attacks,…

TuesdayJul 13, 2021 2:45 pm

Third City in California Wants Psychedelics Decriminalized

Yet another city in California is taking steps to pass a resolution aimed at decriminalizing psychedelics. This comes after a council member from Arcata City, California, agreed to spearhead the reform effort. Last week Decriminalize Nature Humboldt revealed that Sarah Schaefer, a councilmember, had accepted the lead in championing a resolution as it makes its way through the council. Schaefer agreed to support the resolution until there is a policy change that makes the enforcement of laws against entheogenic substances, such as ibogaine and psilocybin mushrooms, the lowest priority for law enforcement agencies. In addition, the group announced that during…

MondayJul 12, 2021 3:00 pm

Harvard Launches First-Ever Psychedelics Policy Center

Earlier this week, the Harvard Law School opened a psychedelics policy center, which it believes will be useful to physicians navigating this growing field as more policies of reform are approved. The Project on Psychedelics Law and Regulation, as the center will be known, has been established to promote equity, innovation and safety in psychedelics therapeutics, commerce and research. A press release by the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard acknowledges that local and state psychedelics development involves assessments of the effects of policy as well as the possible impact of private companies that seek…

MondayJul 12, 2021 12:42 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Marks Major Milestone for its Rapid Point-Of-Care Diagnostic Business Strategy

XPhyto began delivery of approximately 1,000 Covid-ID Lab test kits in Berlin This marks a significant achievement commercially, as well as for the company’s point-of-care diagnostic business strategy The lab tests are designed to offer reliable Covid-19 test results in under 25 minutes XPhyto plans to capitalize on the rapid test market, projected to reach $39.1 billion by 2023 For the week starting June 27, 2021, XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) began delivery of approximately 1,000 Covid-ID Lab test kits to 10 different test centers in Berlin, Germany. This move is a major commercial achievement for the…

FridayJul 09, 2021 2:00 pm

Psychedelics Reemerge as Treatment for Depression in Canada

Research on psychedelics has shown that the substances possess various benefits, some of which can be used to manage mental health conditions such as anxiety, post-traumatic stress disorder and depression. In addition, in Canada individuals who are nearing the end of their lives have been granted exemptions that allow them to use psilocybin as part of their compassionate treatment. A not-for-profit organization headquartered in British Columbia known as TheraPsil has played a crucial role in obtaining most of these exemptions. In addition to this, the organization has also connected patients to doctors and therapists who oversee the use of these…

ThursdayJul 08, 2021 1:04 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leveraging Similar Strategy as Leading Cannabis-Derived Compound Pharmaceutical Company

Jazz Pharmaceuticals’ acquisition of GW Pharma for $7.2 billion in February 2021 shows the massive potential of the drug development industry from naturally-derived compounds Tryp Therapeutics is following in the footsteps of GW with its innovative drug pipeline and the development of psilocybin-based compounds for the treatment of diseases with high unmet medical needs It is one of only a handful of companies moving into Phase 2a clinical trials with a psychedelic compound, and seeks to duplicate the success of GW As of 2020, the global biotech sector was valued at $753 billion. It is further projected to grow at…

ThursdayJul 08, 2021 1:00 pm

Four Clinical Trials That Could Change Treatment for Mental Health Conditions

In the last decade, a lot of clinical research on psychedelic substances has been conducted, with many scientists focusing on their use in treating psychological and mental ailments. This has also led to a surge in investments into psychedelic research, with many results heralding psychedelics as effective alternative medications for various ailments. Before being classified under Schedule I of the Controlled Substances Act in the United States, psychedelics had been used for both medicinal and recreational purposes by different indigenous tribes and cultures for centuries, only becoming popular in Western medicine in the late 1950s and 1960s. Recent studies on…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000